JP2025509680A - 治療薬のバイオアベイラビリティを改善した組成物およびその使用 - Google Patents

治療薬のバイオアベイラビリティを改善した組成物およびその使用 Download PDF

Info

Publication number
JP2025509680A
JP2025509680A JP2024555003A JP2024555003A JP2025509680A JP 2025509680 A JP2025509680 A JP 2025509680A JP 2024555003 A JP2024555003 A JP 2024555003A JP 2024555003 A JP2024555003 A JP 2024555003A JP 2025509680 A JP2025509680 A JP 2025509680A
Authority
JP
Japan
Prior art keywords
weight
saturated
unsaturated
triglycerides
monoglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024555003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509680A5 (cg-RX-API-DMAC10.html
Inventor
グッディング,ダニエル
ブリュー,ジョン
エム. バニスター,ロビン
Original Assignee
ティーアールエックス バイオサイエンシズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/en
Application filed by ティーアールエックス バイオサイエンシズ リミテッド filed Critical ティーアールエックス バイオサイエンシズ リミテッド
Publication of JP2025509680A publication Critical patent/JP2025509680A/ja
Publication of JP2025509680A5 publication Critical patent/JP2025509680A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024555003A 2022-03-14 2023-03-14 治療薬のバイオアベイラビリティを改善した組成物およびその使用 Pending JP2025509680A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
US63/269,330 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (en) 2021-03-27 2022-03-28 Compositions having improved bioavailability of therapeutics
EPPCT/EP2022/058180 2022-03-28
PCT/EP2023/056506 WO2023174948A2 (en) 2022-03-14 2023-03-14 Compositions having improved bioavailability of therapeutics and uses thereof

Publications (2)

Publication Number Publication Date
JP2025509680A true JP2025509680A (ja) 2025-04-11
JP2025509680A5 JP2025509680A5 (cg-RX-API-DMAC10.html) 2026-03-24

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024555003A Pending JP2025509680A (ja) 2022-03-14 2023-03-14 治療薬のバイオアベイラビリティを改善した組成物およびその使用

Country Status (7)

Country Link
EP (1) EP4493151A2 (cg-RX-API-DMAC10.html)
JP (1) JP2025509680A (cg-RX-API-DMAC10.html)
AU (1) AU2023233811A1 (cg-RX-API-DMAC10.html)
CA (1) CA3245873A1 (cg-RX-API-DMAC10.html)
IL (1) IL315617A (cg-RX-API-DMAC10.html)
WO (1) WO2023174948A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA202407659B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4784247A1 (en) * 2023-09-28 2026-08-05 The Regents Of The University Of California Methods and compositions of treating age-related conditions
WO2025093572A1 (en) * 2023-10-29 2025-05-08 TRx Biosciences Limited Solid dispersion compositions and uses thereof
WO2026053168A1 (en) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Amorphous forms of a rock2 inhibitor and formulations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
JP5758630B2 (ja) * 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Parp阻害剤としてのピリダジノン誘導体
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) * 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102813639B (zh) * 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
US9073944B2 (en) * 2012-02-21 2015-07-07 Merck Patent Gmbh Cyclic diaminopyrimidine derivatives
AU2014360537B2 (en) * 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
ES2975417T3 (es) * 2017-03-03 2024-07-05 Inspirna Inc Formulaciones con estabilidad mejorada
WO2020079706A1 (en) * 2018-10-15 2020-04-23 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (en) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Solid dosage form of dasatinib
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Also Published As

Publication number Publication date
ZA202407659B (en) 2026-01-28
IL315617A (en) 2024-11-01
CA3245873A1 (en) 2023-09-21
EP4493151A2 (en) 2025-01-22
WO2023174948A2 (en) 2023-09-21
AU2023233811A1 (en) 2024-09-19
WO2023174948A3 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
AU2023233811A1 (en) Compositions having improved bioavailability of therapeutics and uses thereof
Jiang et al. Ionic Liquids: Promising Approach for Oral Drug Delivery: Jiang et al.
KR20150129664A (ko) 만성 염증 및 염증성 질병을 치료하기 위한 조성물 및 방법
AU2018211966B2 (en) CRAC channel inhibitor compositions
CN103635189A (zh) 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
TW202139984A (zh) 治療性化合物及其調配物與用途
JP2013501806A5 (cg-RX-API-DMAC10.html)
US20200384007A1 (en) Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
TWI696621B (zh) 原肌球蛋白相關激酶(trk)抑制劑之醫藥調配物
JP2024511208A (ja) 治療薬のバイオアベイラビリティを改善した組成物
CN113164402A (zh) 药物制剂
TWI433840B (zh) 醫藥組合物
US20230149362A1 (en) New capsule composition for peroral administration
CN105585569A (zh) 一种恩替卡韦脂肪酸衍生物及其药物组合物
JP2024535596A (ja) ヒト免疫不全ウイルス複製の阻害薬
US20250195433A1 (en) Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof
CN103859395B (zh) 一种高吸收率的辅酶q10的自乳化释药体系及其制备方法及应用
CN103781478A (zh) 用以改善酯类前药吸收率的方法与改良的药学组合物
JP5936609B2 (ja) キナーゼインヒビターの経口製剤
US20250195461A1 (en) Fibrate Compositions for Treating Inflammation and Neuroinflammation
JP2024528195A (ja) ブラジキニンb2受容体拮抗薬を経口投与するための脂質ベースの組成物
US10064883B2 (en) Lipiodol-based anti-tumour emulsion for treating cancer
CN101573111A (zh) 磷脂酶抑制剂的制剂
CA3188796A1 (en) Thromboxane receptor antagonist formulations
WO2023174941A1 (en) Fibrate compositions for treating inflammation and neuroinflammation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260313